SGLT2, sodium-glucose cotransporter-2; SGLT2i, sodium-glucose cotransporter-2 inhibitors; T2D, type 2 diabetes; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; ASCVD, atherosclerotic cardiovascular disease; EF, ejection fraction; hHF, hospitalization for heart failure; ATP, adenosine triphosphate. This evidence concerns the gene SLC5A2 and atherosclerosis.